Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7.

Kondo M., Hoshi S.L., Ishiguro H., Toi M.

The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.

Read more: Economic Evaluation of the 70-gene Prognosis-Signature…Kondo et al_Breast Cancer Research and Treatment 2012